恩瑞格该怎么使用呢？

The common starting dose of dispersible tablets is 20 mg/(kg·d). If there is a large amount of blood transfusion and the iron increase is >0.5 mg/(kg·d) or the iron load before treatment is high, the recommended dose is 30 mg/(kg·d). If the iron increase is <0.3 mg/kg, 10-15 mg/kg/d is enough to control the disease. Administer on an empty stomach 30 minutes before meals and should be completely dissolved in water or apple or orange juice. Drug interactions: 1. Avoid combination with strong inducers of UDP-glucuronyltransferase (UGT) (such as rifampicin, phenytoin, sedatives and hypnotics, protease inhibitors), cholestyramine. 2. It cannot be administered at the same time as aluminum-containing antacids. Not to be combined with other iron chelation treatments. 3. Be careful with repaglinide, drugs with potential ulcerogenic effects such as NSAIDs, cortisones, or oral bisphosphonates, drugs metabolized by CYP3A4 (such as cyclosporine, simvastatin, hormonal contraceptives). Withhold Enrig dispersible tablets at least 5 days before performing gallium-67 imaging.

Patients with Renal Impairment: Caution must be exercised during treatment with Enriga dispersible tablets in patients with serum creatinine levels above the upper limit of the normal range for age. It should be used with particular caution in patients with creatinine clearance between 40 and 60 mL/min, especially in the presence of other risk factors that may impair renal function such as concomitant medications, dehydration, or severe infection. The recommended starting dose for patients with renal impairment is as described above. Patients' serum creatinine should be monitored monthly and the daily dose reduced by 10 mg/kg if necessary.

Patients with Hepatic Impairment: Dispersible tablets have been studied in subjects with hepatic impairment. For patients with moderate hepatic impairment (Child-Pugh B), the starting dose should be reduced by approximately 50%. Patients with severe hepatic impairment (Child-Pugh C) should not use Enriga dispersible tablets. Liver function should be tested in all patients before starting treatment, every two weeks for the first month of treatment, and monthly thereafter. Pediatric Patients: Dosage recommendations for pediatric patients are consistent with those for adult patients. Changes in the pediatric patient's weight over time must be taken into account when calculating dosage. Geriatric Patients: Dosage recommendations for geriatric patients are consistent with those described above. In clinical trials, elderly patients experience adverse reactions more frequently than younger patients and should be closely monitored for adverse reactions that may require dose adjustment.